Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Reinisch

Showing results (291-300 of 352) with videos related to

Pageof 36
Sort By:
Lancet (London, England)|August 2, 2016
Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trialJulián Panés, Damián García-Olmo, Gert Van Assche, et al.
The New England Journal of Medicine|May 4, 2017
Tofacitinib as Induction and Maintenance Therapy for Ulcerative ColitisWilliam J Sandborn, Chinyu Su, Bruce E Sands, et al.
Gastroenterology|May 20, 2020
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International RegistryErica J Brenner, Ryan C Ungaro, Richard B Gearry, et al.
Inflammatory Bowel Diseases|October 24, 2019
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's DiseaseJames D Lewis, Paul Rutgeerts, Brian G Feagan, et al.
Advances in Therapy|May 25, 2022
MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory DiseasesWayne J G Hellstrom, Radboud J E M Dolhain, Timothy E Ritter, et al.
Inflammatory Bowel Diseases|May 1, 2026
Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trialAnita Afzali, Silvio Danese, Remo Panaccione, et al.
Journal of Crohn'S & Colitis|May 20, 2026
Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensusPauline Wils, Vipul Jairath, Bruce E Sands, et al.
Inflammatory Bowel Diseases|January 15, 2022
The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend AnalysisGilaad G Kaplan, Fox E Underwood, Stephanie Coward, et al.
Gastroenterology|June 16, 2010
Inflammatory bowel disease is a risk factor for recurrent venous thromboembolismGottfried Novacek, Ansgar Weltermann, Anna Sobala, et al.
The New England Journal of Medicine|May 24, 2023
Upadacitinib Induction and Maintenance Therapy for Crohn's DiseaseEdward V Loftus, Julian Panés, Ana P Lacerda, et al.
Pageof 36

Showing results (291-300 of 352) with videos related to

Sort By:
Pageof 36
Lancet (London, England)|August 2, 2016
Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trialJulián Panés, Damián García-Olmo, Gert Van Assche, et al.
The New England Journal of Medicine|May 4, 2017
Tofacitinib as Induction and Maintenance Therapy for Ulcerative ColitisWilliam J Sandborn, Chinyu Su, Bruce E Sands, et al.
Gastroenterology|May 20, 2020
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International RegistryErica J Brenner, Ryan C Ungaro, Richard B Gearry, et al.
Inflammatory Bowel Diseases|October 24, 2019
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's DiseaseJames D Lewis, Paul Rutgeerts, Brian G Feagan, et al.
Advances in Therapy|May 25, 2022
MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory DiseasesWayne J G Hellstrom, Radboud J E M Dolhain, Timothy E Ritter, et al.
Inflammatory Bowel Diseases|May 1, 2026
Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trialAnita Afzali, Silvio Danese, Remo Panaccione, et al.
Journal of Crohn'S & Colitis|May 20, 2026
Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensusPauline Wils, Vipul Jairath, Bruce E Sands, et al.
Inflammatory Bowel Diseases|January 15, 2022
The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend AnalysisGilaad G Kaplan, Fox E Underwood, Stephanie Coward, et al.
Gastroenterology|June 16, 2010
Inflammatory bowel disease is a risk factor for recurrent venous thromboembolismGottfried Novacek, Ansgar Weltermann, Anna Sobala, et al.
The New England Journal of Medicine|May 24, 2023
Upadacitinib Induction and Maintenance Therapy for Crohn's DiseaseEdward V Loftus, Julian Panés, Ana P Lacerda, et al.
Pageof 36